Pramipexole, a clinically common drug for treating Parkinson's disease, has favorable inhibitory effects on the neuronal inflammation and apoptosis in the brain tissues of the Parkinson's disease model rats, while effectively up-regulating the expressions of BDNF, miR-103a and miR-30b, which is likely to be one mechanism of pramipexole in treating Parkinson's disease. The gene discussed is BDNF; the disease is Parkinson disease.